The European Union operates a harmonised pharmaceutical framework under EMA oversight, but "harmonised" does not mean "identical". Each member state's national competent authority (NCA) applies EU directives through its own national legislation, with distinct enforcement priorities, import control regimes, and interpretations of what constitutes a medicinal product versus a research chemical.
For English-speaking researchers working across multiple European jurisdictions — or relocating between countries — understanding these national variations is essential. This entry provides a practical overview of the verification landscape in each major European country, based on publicly available NCA information as of July 2026.
The Shared Foundation: What Is Common Across EU Member States
Before examining national variations, it is worth establishing what is genuinely consistent across EU member states:
- EMA-authorised medicinal products are valid across all EU/EEA member states by definition — no further national authorisation is needed for an EMA-approved product
- EU Directive 2001/83/EC (the Community code on medicinal products) forms the legal basis for all national pharmaceutical regulation
- Research-use-only substances are not covered by EU pharmaceutical harmonisation — they fall under national law, chemical regulation, and in some cases narcotics/controlled substance legislation
- All member states require that potent pharmacologically active substances be used under medical supervision when used therapeutically
Country-by-Country Reference
The AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) operates under Royal Decree 870/2013 and EU pharmaceutical law. Spain has been particularly active in enforcing against unauthorised peptide sales, with multiple AEMPS alerts issued regarding GLP-1 analogues sold outside authorised channels. Research import requires formal AEMPS authorisation under the Ley de Garantías. COA verification is practically essential given Spain's position as a significant point of entry for counterfeit products from third countries.
The BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) administers Germany's Arzneimittelgesetz (AMG), one of the most stringent pharmaceutical laws in Europe. Germany's interpretation of what constitutes a medicinal product is broad — a substance that is presented as having pharmacological effects can be classified as a medicine regardless of its stated research purpose. Import of non-authorised substances requires specific BfArM authorisation. German customs enforcement is rigorous. Independent COA verification is critical for any research procurement.
The ANSM (Agence nationale de sécurité du médicament et des produits de santé) supervises medicines safety in France under the Code de la santé publique. French pharmaceutical law aligns closely with EU directives but has specific provisions regarding substances with a significant pharmacological action. The ANSM has issued specific alerts regarding peptides mimicking authorised GLP-1 products. Research use requires protocol-level authorisation for institutional research settings.
AIFA (Agenzia Italiana del Farmaco) governs medicines regulation in Italy and has a significant role in EMA's CHMP scientific committees. Italy's legislative decree implementing EU pharmaceutical directives broadly follows the EU framework. AIFA enforcement against non-authorised GLP-1 analogues has increased since 2024. Research import authorisations are granted under specific AIFA provisions for institutional research.
The CBG-MEB (College ter Beoordeling van Geneesmiddelen) operates under the Geneesmiddelenwet (Medicines Act). The Netherlands has a tradition of nuanced interpretation of the research/medicine boundary, but CBG-MEB's position on unauthorised medicinal substances is unambiguous: substances presenting as having pharmacological effects require authorisation. The CBG-MEB has significant EMA influence given the Netherlands' role as EMA host country since 2019.
The URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych) administers Polish pharmaceutical law (Prawo farmaceutyczne). Poland has seen significant growth in both the research peptide market and in NCA enforcement activity. URPL alerts regarding GLP-1 analogues and falsified products have increased. Research institutions require formal URPL authorisation for import of non-authorised substances.
The Läkemedelsverket (Swedish Medical Products Agency, MPA) administers the Läkemedelslagen (Medicines Act). Sweden's regulatory approach is methodical and risk-based. The MPA has issued guidance on the boundary between research chemicals and medicinal products. Research use under formal institutional protocols is the expected framework for any work involving pharmacologically active substances.
The HPRA (Health Products Regulatory Authority) applies Irish medicines legislation (Medicinal Products regulations) implementing EU directives. Ireland's common law tradition and English-language environment make it an important market for pan-European researchers. HPRA has been active in issuing alerts against falsified GLP-1 products. As with all EU member states, the research/medicine distinction is enforced by the NCA.
Post-Brexit, the MHRA (Medicines and Healthcare products Regulatory Agency) operates as Great Britain's independent medicines regulator under the Human Medicines Regulations 2012. Northern Ireland retains access to EMA authorisations under the Windsor Framework. The MHRA has been particularly prominent in communicating risks associated with unregulated GLP-1 analogues, issuing multiple public safety communications from 2023 onwards. UK pharmaceutical law is substantively equivalent to EU law but diverging in detail. MHRA enforcement on counterfeit and unlicensed products is active and well-resourced.
Norway participates in the EEA, meaning EMA-authorised products apply under the EEA Agreement's pharmaceutical annexe. The DMP (Statens Legemiddelverk / Norwegian Medicines Agency) administers Norwegian pharmaceutical law (Legemiddelloven). For RUO substances, Norwegian law applies without the EEA umbrella. DMP enforcement aligns broadly with Nordic regulatory norms — methodical, risk-proportionate, and well-documented.
The Lægemiddelstyrelsen (Danish Medicines Agency, DKMA) administers Danish medicines law (Lægemiddelloven) within the EU pharmaceutical framework. Denmark has been active in European coordination on GLP-1 analogue counterfeiting, given the significance of Novo Nordisk — manufacturer of semaglutide (Ozempic®/Wegovy®) — as a Danish company and EMA reference holder for several relevant products.
Switzerland's Swissmedic administers the Heilmittelgesetz (HMG) — an independent regulatory framework that is substantively aligned with but formally separate from EU pharmaceutical law. Swiss pharmaceutical regulation is rigorous by any international standard. Swissmedic's product authorisation database (AIPS) documents authorised products. For research use, Swiss law requires specific authorisation for import and use of non-approved pharmacologically active substances. Switzerland's non-EU status means EMA authorisations do not automatically apply.
The Universal Constant
Despite the national variation catalogued above, one principle is consistent across every jurisdiction in this compendium: no regulatory framework in Europe endorses the unsupervised human use of pharmacologically active substances outside the approved healthcare system. The variation is in enforcement intensity, the specific legal mechanisms, and the degree to which research exemptions are available — not in the fundamental position that medical supervision is required.
Independent analytical verification (HPLC + LC-MS) remains the minimum quality check applicable regardless of jurisdiction. The regulatory status of a substance varies by country; the need to verify what that substance actually is does not.